Evidence map›Paper›PMID 22796110›Full record

ReviewNeuropharmacology2013

Leveraging the cortical cholinergic system to enhance attention.

Elise Demeter, Martin Sarter

Open access · greenAbstract readReview
In one paragraph

Review in Neuropharmacology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
36citing papers in PubMed, 1 pooled it
4.0field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

36 citing papers in PubMed, 1 synthesis or guideline pooled it, 74 citations in OpenAlex.

  1. Pooled it
  2. Genetic and epigenetic signatures associated with plasma oxytocin levels in children and adolescents with autism spectrum disorder.Autism research : official journal of the International Society for Autism Research · 2023
    Trial
  3. Event-related potential (P300): the effects of levetiracetam in cognitive performance.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2021
    Trial
  4. Trial
  5. Trial
  6. Review
  7. Article
  8. Article
  9. Article
  10. A Little "Re-Cognition" Goes a Long Way for Pro-Cognitive Therapeutics in Alcohol Studies.The Journal of pharmacology and experimental therapeutics · 2024
    Article
  11. Review
  12. Article
  13. Lower cholinergic basal forebrain volumes link with cognitive difficulties in schizophrenia.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2021
    Article
  14. Review
  15. Article
  16. Review
  17. Article
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Elise DemeterPsychiatry Department, 4250 Plymouth Road, University of Michigan, Ann Arbor, MI 48109-5765, USA. emd7@duke.edu
Martin Sarter
University of Michigan–Ann Arbor · US

Funding

DA/GABA MODULATION OF CORTICAL ACH RELEASER01MH057436 · NIMH · OHIO STATE UNIVERSITY · PI BRUNO, JOHN P · 1998 to 2010
$2.9M
Choline transporter capacity limits motivated behavior on mice, rats, and humansR01MH086530 · NIMH · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI SARTER, MARTIN F · 2010 to 2014
$1.9M
NIMH NIH HHS R01 MH057436NIMH NIH HHS R01 MH086530
6 · The paper itself

Abstract

Attentional impairments are found in a range of neurodegenerative and neuropsychiatric disorders. However, the development of procognitive enhancers to alleviate these impairments has been hindered by a lack of comprehensive hypotheses regarding the circuitry mediating the targeted attentional functions. Here we discuss the role of the cortical cholinergic system in mediating cue detection and attentional control and propose two target mechanisms for cognition enhancers: stimulation of prefrontal α4β2* nicotinic acetylcholine receptors (nAChR) for the enhancement of cue detection and augmentation of tonic acetylcholine levels for the enhancement of attentional control. This article is part of a Special Issue entitled 'Cognitive Enhancers'.

Indexed as

AnimalsAttentionCholinergic NeuronsCholinesterase InhibitorsCognition DisordersHumansMolecular Targeted TherapyMuscarinic AgonistsNerve Tissue ProteinsNicotinic AgonistsNootropic AgentsPerformance-Enhancing SubstancesPrefrontal CortexCholinesterase InhibitorsMuscarinic AgonistsNerve Tissue ProteinsNicotinic AgonistsNootropic AgentsPerformance-Enhancing Substances

Identifiers

PMID22796110
PMCPMC3445745
OpenAlexW1971280731

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.